The trial to examine the effects of puberty blocking drugs in the UK has been delayed until early next year, raising concerns about the safety and ethical implications of these treatments.
Dr. Hilary Cass's report highlighted the lack of evidence on the safety and potential harm of puberty blockers, cautioning the NHS to be extremely careful before administering these drugs to young people.
The intention to enroll patients in the trial recommended by Dr. Cass has sparked controversy, with gender campaign groups like Sex Matters expressing ethical concerns about the known risks of permanent damage associated with puberty blockers.
Previous government stances have been cautious about the use of puberty blockers, with concerns raised regarding their safety and efficacy in treating young patients with gender incongruence.
Collection
[
|
...
]